Multidrug treatment prevents the evolution of drug resistance
While multidrug regimens are commonly deployed to slow or manage resistance, they do not universally prevent its evolution, as numerous clinical and laboratory studies demonstrate that pathogens and cancer cells consistently find pathways to develop resistance under multi-agent pressure.
The claim states that multidrug treatment prevents the evolution of drug resistance. Multiple provided papers directly refute this by demonstrating that multidrug regimens and combination therapies frequently encounter the emergence of drug resistance (e.g., HIV combination therapy resistance, cancer therapies selecting for adaptive mutability and persister cell survival, tuberculosis drug resistance despite decades of multidrug regimens, and multi-antibiotic usage being a risk factor for multidrug-resistant bacterial infections). Therefore, the evidence clearly weighs against the absolute claim that multidrug treatment prevents resistance evolution.
gutrani GKA, Al-Ojali SM. Long-Term Effectiveness of combination Antiretroviral Therapy and Drug Resistance Patterns Among People living with HIV in Benghazi, Libya: Retrospective cohort Study (2009 – 2014). 2026. https://doi.org/10.21203/rs.3.rs-10245750/v1
This study demonstrates that despite the use of combination antiretroviral therapy, significant rates of multidrug resistance still emerge and persist in clinical settings.
See more details
Fabbri L, Lagadec L, Guérin E, Lecourt H, Baille D, Besse L, Messaoudi C, Désaubry L, Abou-Hamdan H, Roy S, Lombard B, Loew D, Scoazec JY, Robert C, Vagner S. Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.. 2026. https://doi.org/10.1038/s44321-026-00479-5
The paper explains that cancer cells undergoing combination targeted therapies can adapt and increase their mutation rates, ultimately evolving into resistant phenotypes.
Liu Y, Zhao K, Hu B, Tan J, Yang Z, Vasilopoulos T, Luo N, Ku Y, Zhou G, Wei S, Zhang J, Zhou W, Li S, Herbig U, Liu L, Zhang G. A telomerase-SUCLG2 signaling axis drives drug resistance by protecting persister cells.. 2026. https://doi.org/10.1016/j.celrep.2026.117668
Research shows that persister cells can survive combined targeted therapies and evolve into fully drug-resistant clones via telomerase and metabolic adaptations.
Waller NJE, Rhee KY. From Empirical Discovery to Targeted Therapy: The Evolution of Tuberculosis Treatment.. 2026. https://doi.org/10.1101/cshperspect.a041821
The review notes that despite long-standing guidelines requiring multidrug treatment for tuberculosis, the emergence and spread of drug-resistant strains continue to erode clinical efficacy.
Hong X, Zhou S, Cai Q, Cai Y, Chen Z, Zhao W, Ye Y, Dai X. Burn Wound Infections With Staphylococcus aureus: Clinical Characteristics and Risk Factors for Methicillin-Resistant Strains.. 2026. https://doi.org/10.1111/iwj.70978
Multivariate analysis in this clinical study identifies the use of multiple antibiotic types as an independent risk factor for selecting multidrug-resistant bacterial infections.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt